Search | Clinical Trials Finder

Conditions: Wounds and Injuries
Interventions: Processed Amniotic Fluid, Standard of Care Wound Treatment Regimen; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Type 1 Diabetes Mellitus
Interventions: LY2605541, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Concord, California • Escondido, California • Fresno, California + 14 more

Conditions: Autism Spectrum Disorders
Interventions: Arbaclofen; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 5 more

Conditions: Malignant Glioma, Brain Tumor, Recurrent
Interventions: D2C7-IT; Drug
Lead sponsor: Darell Bigner; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cardiac Failure, Renal Failure, Kidney Failure
Interventions: Protocolized Diuretic Strategy; Drug
Lead sponsor: Kelly V. Liang, MD; Other
Eligibility: 21 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Solid Tumor, Lymphoma
Interventions: TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel; Drug
Lead sponsor: Trishula Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Orange, California • Sacramento, California • San Francisco, California + 12 more

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Rapid-Acting Insulin, Long acting insulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 15 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Adverse Events, Pharmacokinetic Variables
Interventions: ABT-143, ABT-335 and rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency
Interventions: Immunoglobulins Intravenous (Human); Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 4 Years to 71 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 10
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 7 more

Conditions: Knee Arthritis
Interventions: Methylprednisolone, Standard of Care; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia • Tucker, Georgia

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab (investigational), Placebo, Methotrexate (MTX); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more

Conditions: Knee Osteoarthristis, ACL Injuries, Post-Traumatic
Interventions: extracorporeal shockwave therapy (ESWT), Sham Comparator; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Cancer
Interventions: TTX-080, pembrolizumab, cetuximab, FOLFIRI; Drug
Lead sponsor: Tizona Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 41
States / cities: Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more

Conditions: Solid Tumors, Adult
Interventions: JAB-8263; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Denver, Colorado • Lake City, Florida • Nashville, Tennessee

Conditions: Immunologic Deficiency Syndrome
Interventions: Immune Globulin Intravenous (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more

Conditions: Epilepsy, Cognitive Deficits, Attention Deficits
Interventions: Methylphenidate; Drug
Lead sponsor: Kimford Jay Meador; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission
Interventions: Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Questionnaire Administration, Study of Socioeconomic and Demographic Variables; Behavioral · Other · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 124
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 105 more

Conditions: Obesity
Interventions: Propofol and Fentanyl administration; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Heart Diseases, Left Ventricular Dysfunction
Interventions: Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 30 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Acute Myeloid Leukemia
Interventions: AZD1152, LDAC (low dose cytosine arabinoside); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 60 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Asthma
Interventions: BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 2,274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 107
States / cities: Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Interventions: 4-factor prothrombin complex concentrate (4FPCC); Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 125 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Search by objective public record fields.

Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds

A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

D2C7 for Adult Patients With Recurrent Malignant Glioma

Protocolized Diuretic Strategy in Cardiorenal Failure

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Methylprednisolone Taper After Total Knee Replacement

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Methylphenidate Treatment of Attention Deficits in Epilepsy

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal